Focusing on the epidemiology of this type of neoplasm, our purpose is to define the distribution of KIT, PDGFR-alpha and BRAF mutations in a population-based cohort of GIST and correlate them with risk classifications and survival. This evidence concerns the gene KIT and gastrointestinal stromal tumor.